

# Clinical Neurological Society of America 50<sup>th</sup> Annual Meeting

- January 13-16, 2024



- This activity is jointly provided by Global Education Group and Clinical Neurological Society of America.
- This activity is supported by an educational grant from Sanofi, Kyowa Kirin, Inc. And Eisai Inc.

## PROGRAM MATERIALS REQUIREMENTS

### Target Audience

The CNSA Annual Meeting is designed to provide practicing neurologists with the most up-to-date information for the diagnosis and management of the patient with neurologic conditions. Each section is built around a specific clinical topic and presented by experts who provide practical information for evaluating and treating patients with neurological conditions.

This meeting is designed primarily for practicing neurologists. Other health care providers that can benefit from this meeting include residents, fellows, physician assistants, nurse practitioners, nurses, neurosurgeons, psychiatrists, social workers, doctors of pharmacy and neuropsychologists who work in patient care

### Statement of Need/Program Overview

To be more capable of practicing at the standard of care, neurologists need a better understanding of the pathophysiology of stroke and cerebrovascular disease, epilepsy and seizure disorders, neuroinflammatory disorders, movement disorders, neuromuscular disorders, dementias, headache disorders and emerging neurological illnesses. They also need improved diagnostic evaluation, treatment and management strategies, and novel approaches to monitoring pediatric and adult patients with these conditions. This educational activity is designed to improve understanding and use of current clinical practice guidelines and recent research findings in the participant's practice.

### Educational Objectives

*After completing this activity, the participant should be better able to:*

- Identify and differentiate primary headache syndromes by current classification.
- Explain new medications and strategies for treating headache and migraine disease.
- Describe the etiologies, treatment and outcomes of pediatric migraine.
- Describe various stroke syndromes and strategies for acute stroke management.
- Outline strategies for diagnosing and managing patients in non-convulsive status epilepticus.
- Describe the etiologies, treatment and outcomes of special patient populations with epilepsy.
- Identify the signs, symptoms and treatments for Rett syndrome.
- Discuss strategies for diagnosis and management of vertigo and dizziness.
- Explain new approaches to patient care related to tele-neurology, digital health and artificial intelligence.
- Describe clinical updates and new treatments related to hypokinetic (i.e. Parkinson's disease) and hyperkinetic movement disorders.
- Explain the latest literature relative to prevention of cognitive decline and brain health.
- Discuss strategies for achieving accurate dementia diagnoses.
- Explain new medications and strategies for treating Alzheimer's disease.
- Describe advances in the diagnosis and treatment of neuromuscular diseases, including myasthenia gravis, ALS and DMD.
- Describe advances in the diagnosis and treatment of neuroimmunological diseases, including multiple sclerosis subtypes and autoimmune encephalitis.
- Explain updated clinical guidelines related to the management of diabetic and inflammatory neuropathies.

## **Program Agenda**

An updated agenda and scientific program are available [here](#).

## **Physician Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Clinical Neurological Society of America. Global is accredited by the ACCME to provide continuing medical education for physicians.

## **Physician Credit Designation**

Global Education Group designates this live activity for a maximum of 17 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

## **Instructions for Obtaining Credit**

Participants of the live event will be able to claim credit up to a maximum of 17.0 *AMA PRA Category 1 Credits™*. In order to receive credit, participants must complete the meeting evaluation and credit claim application following the conclusion of the event. A link to the survey will be emailed to participants at the email address provided during registration. Statements of participation or credit will be emailed by Global Education Group, CNSA's CME provider, 4-6 weeks following the program.

## **System Requirement**

### **PC**

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)  
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)  
512 MB of RAM (1 GB recommended)  
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome  
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

### **MAC**

1.83 GHz Intel Core Duo or faster processor  
512 MB of RAM (1 GB recommended)  
MAC OS X 10.12, 10.13 and 10.14  
Mozilla Firefox, Apple Safari, Google Chrome  
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

## **Fee Information& Refund/Cancellation Policy**

Fees for this educational activity: Associate Member: \$550 General Member: \$700 Non Member: \$850 Registration can be refunded in full by November 22. If cancelled after November 22, a 50% partial refund will be accommodated. To request a refund, please contact Nina Perez, [nina@neuroamerica.org](mailto:nina@neuroamerica.org).

## **Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and

Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **Faculty** have the following relevant financial relationships with ineligible companies:

<b>Name of Faculty or Presenter</b>	<b>Reported Financial Relationship</b>
Larry Charleston, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Allergan/AbbVie, Alder/Lundbeck, Amneal, Biohaven, Haleon, Satsuma, Teva <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Amgen
Frank Garrett Conyers, MD	Nothing to Disclose
Robin Davis, MD	Nothing to Disclose
John Schreiber, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Neurocrine Biosciences, Inc, Denali Therapeutics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Stoke Therapeutics, Eisai, UCB, Neurocrine Biosciences, Inc <b>Speakers' Bureau:</b> Marinus Pharmaceuticals, UCB
Fawad Khan, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Eisai, Zimmer Biomet, LivaNova, Neurelis, Inc, Lundbeck, Pfizer <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Amgen, Teva Pharmaceutical, Biohaven Pharmaceutical, Marinus, UCB, Lundbeck, Abbvie <b>Honoraria:</b> Natus, Stratus <b>Speakers' Bureau:</b> Amgen, UCB, SK Life Science, Lundbeck, Allergan, Lilly USA, Impel Pharmaceuticals, AbbVie
Mohamed Koubeissi, MD	Nothing to Disclose
Mitesh Lotia, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Orphalan <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Roche, Intracellular Therapies, Biogen <b>Speakers' Bureau:</b> Abbott
David Houghton, MD	Nothing to Disclose
William Kilgo, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Genentech, EMD Serono, Alexion, Bristol Meyers Squibb <b>Honoraria:</b> Octave Biosciences, TG Therapeutics <b>Speakers' Bureau:</b> Genentech, Biogen, TG Therapeutics
Bassam Bassam, MD	<b>Speakers' Bureau:</b> UCB Pharma Company, Argenx biotechnology Company
James Eaton, MD	Nothing to Disclose
Francesca Bagnato, MD	Nothing to Disclose
Mohamed Kazamel, MD	Nothing to Disclose
Paige Kalika	Nothing to Disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at Clinical Neurological Society of American have no relevant financial relationships to disclose.

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Clinical Neurological Society of America do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.